BTLA

Avalo Reports 2023 Financial Results and Provides Business Updates

Retrieved on: 
Friday, March 29, 2024
Exercise, Patient, Research, Acquisition, Inflammation, Net, HS, Therapy, OrbiMed, Hidradenitis suppurativa, Phase II, BTLA, Pharmaceutical industry

Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 million

Key Points: 
  • Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 million
    WAYNE, Pa. and ROCKVILLE, Md., March 29, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and year-end financial results for 2023.
  • The progress we made in 2023 to strengthen our balance sheet helped enable these transactions.
  • “Our focus in 2024 is executing operationally on the development of AVTX-009 for the treatment of hidradenitis suppurativa.
  • As of December 31, 2023, Avalo had $7.4 million in cash and cash equivalents.

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 11, 2024
Therapy, SAN, Ulcerative colitis, Week, CDAI, B cell, Atopic dermatitis, BTLA, Q2, PD-1, Inflammation, Annual general meeting, AAD, UC, Idealized cognitive model, Rheumatoid arthritis, IGA, Patient, BDCA2, IND

“We will have a number of important events in 2024 including the top-line data readout of ANB032's Phase 2b trial in atopic dermatitis by year end,” adds Faga. “We also plan to move our third and fourth ICMs -- ANB033, our anti-CD122 antagonist, and ANB101 -- into the clinic this year, with IND filings planned for Q2 and H2, respectively.”

Key Points: 
  • “Enrollment is ongoing in three global Phase 2 trials for ANB032, our BTLA agonist, in atopic dermatitis and rosnilimab, our PD-1 agonist, in rheumatoid arthritis and ulcerative colitis.
  • The decrease relates primarily to cash used for operating activities and the $50 million stock repurchase program.
  • The change is due primarily to increased royalties recognized for sales of Jemperli offset by one development milestone achieved for cobolimab in 2022.
  • Acquired in-process research and development of $7.3 million for the three and twelve months ended December 31, 2023 related to the exclusive licensing agreement with Centessa Pharmaceuticals.

Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting

Retrieved on: 
Thursday, February 29, 2024
Therapy, SAN, Atopic dermatitis, BTLA, Conference, AAD, Webcast, Poster, American Academy, Vaccine

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will participate in a panel discussion at TD Cowen’s 44th Annual Health Care Conference.

Key Points: 
  • SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will participate in a panel discussion at TD Cowen’s 44th Annual Health Care Conference.
  • Additionally, the company announced an upcoming presentation at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, CA, March 8-12, 2024.
  • Date and Time – Tuesday, March 5, 2024 at 2:10pm ET / 11:10am PT
    A live webcast of the panel discussion will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/events .
  • The company’s planned activities are listed below and the full preliminary program is available online on the AAD website.

Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, November 9, 2023
BTLA, Respiratory failure, Ares, Mortality, Research, Rover 800 series, John Avalos, Ulcerative colitis, COVID-19, Risk, AUG, Safety, Therapy, Patient, Mab, NEA, Pharmaceutical industry, Security (finance), Vaccine, IND, Hook effect

Additionally, we look forward to progressing AVTX-008, our BTLA agonist fusion protein with high-binding affinity and serum stability, to IND.

Key Points: 
  • Additionally, we look forward to progressing AVTX-008, our BTLA agonist fusion protein with high-binding affinity and serum stability, to IND.
  • The Company previously announced it entered into a purchase agreement with AUG to divest the 800 Series on September 12, 2023.
  • Third Quarter 2023 Financial Update:
    Avalo had $10.2 million in cash and cash equivalents as of September 30, 2023.
  • The Company raised $46.2 million of net proceeds from equity financings in the nine months ended September 30, 2023.

Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 2, 2023
Week, Therapy, CDAI, BTLA, Atopic dermatitis, PD-1, Patient, Rheumatoid arthritis, RA, SAN, Ulcerative colitis, Pharmaceutical industry

Initiated a global Phase 2b trial to treat rheumatoid arthritis (RA) with rosnilimab, our PD-1 agonist

Key Points: 
  • Initiated a global Phase 2b trial to treat rheumatoid arthritis (RA) with rosnilimab, our PD-1 agonist
    SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the third quarter ended September 30, 2023 and provided a business update.
  • “We’ve made strong progress this quarter executing against our multi-year plan to develop best-in-class immune cell modulators to drive differentiated clinical outcomes in heterogeneous, systemic autoimmune and inflammatory diseases,” said Daniel Faga, president and chief executive officer of Anaptys.
  • The decrease relates to cash used for the $50 million stock repurchase program and operating activities.
  • The increase was due primarily to manufacturing and development costs for rosnilimab, ANB032 and ANB033.

Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

Retrieved on: 
Wednesday, October 11, 2023
Congress, European Academy of Allergy and Clinical Immunology, BTLA, Therapy, Atopic dermatitis, CEST, SAN, Vaccine, Dermatology

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcoming presentations at the 32nd European Academy of Dermatology and Venerology (EADV) Congress in Berlin, Germany, Oct. 11-14, 2023.

Key Points: 
  • SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcoming presentations at the 32nd European Academy of Dermatology and Venerology (EADV) Congress in Berlin, Germany, Oct. 11-14, 2023.
  • The oral presentation will focus on ANB032’s previously reported healthy volunteer Phase 1 data and the trial-in-progress poster presentation will focus on ANB032’s Phase 2b study in moderate to severe atopic dermatitis.
  • The company’s planned activities are listed below and the full preliminary program is available online on the EADV website.
  • ANB032, a novel BTLA agonist monoclonal antibody, inhibits T cell proliferation, reduces inflammatory cytokines, and down modulates BTLA expression on circulating T and B cells: Results from a first-in-human Phase 1 study (abstract #5603)
    Session Date and Time – Friday, Oct. 13, 2023 from 8:30am – 10:40am CEST

Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation

Retrieved on: 
Tuesday, September 26, 2023
Professional, Biotechnology, John Avalos, Research, BTLA, Acquisition, MD, Patient, Mab, Growth, Therapy, Pharmaceutical industry

Dr. Garry A. Neil, MD, Chief Executive Officer, and Chairman of the Board at Avalo Therapeutics, expressed his enthusiasm about this crucial financial achievement, stating, "Eliminating our $35 million debt is a testament to the dedication and hard work of our entire team.

Key Points: 
  • Dr. Garry A. Neil, MD, Chief Executive Officer, and Chairman of the Board at Avalo Therapeutics, expressed his enthusiasm about this crucial financial achievement, stating, "Eliminating our $35 million debt is a testament to the dedication and hard work of our entire team.
  • With a strengthened balance sheet, the company is well-positioned to pursue collaborations, expand research efforts, and bring innovative treatments to market.
  • It addresses an increasingly recognized and important target for a variety of immune diseases as evidenced by Gilead’s $405 million acquisition of MiroBio.
  • We are proud of our role in helping promising emerging companies, like Avalo, achieve their financial goals and wish Avalo Therapeutics much future success.”

Fierce Biotech Names HiFiBiO Therapeutics a “Fierce 15” Biotech Company of 2023

Retrieved on: 
Monday, August 28, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, TNFR2, Probability, Therapy, Face, Health care, Multimedia, Immunotherapy, Doctor of Philosophy, Creativity, BTLA, OX40, Patient, Pharmaceutical industry

HiFiBiO Therapeutics, a clinical stage global biotech company focusing on improving patient lives with single cell precision, today announced that Fierce Biotech has named it as one of 2023’s “Fierce 15” biotechnology companies.

Key Points: 
  • HiFiBiO Therapeutics, a clinical stage global biotech company focusing on improving patient lives with single cell precision, today announced that Fierce Biotech has named it as one of 2023’s “Fierce 15” biotechnology companies.
  • View the full release here: https://www.businesswire.com/news/home/20230828615800/en/
    “HiFiBiO Therapeutics is at the forefront of harnessing single-cell insights to bring innovative immunomodulatory therapeutics into the clinic,” remarked Liang Schweizer, PhD, Founder, Chairperson, and CEO of HiFiBiO Therapeutics.
  • Since 2017, HiFiBiO Therapeutics has built a sustainable pipeline targeting key mechanisms of immune modulation, with eight clinical candidates discovered, mainly across oncology and autoimmune diseases.
  • “For the past 21 years, we have assessed hundreds of early-stage companies for inclusion in the 'Fierce 15' special report.

AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 7, 2023
SAB, GSK, RA, Therapy, Roche, Infection, Coronavirus Scientific Advisory Board, Saṃsāra, Immunology, G&A, Atopic dermatitis, R, BTLA, IGA, Endometrial cancer, Federation, Translational medicine, Flagship Pioneering, Acquisition, Patient, Investment, SAN, MSI-H, GPP, PD-1, Federation of Clinical Immunology Societies, Collaboration, AD, Research, Autoimmunity, Rheumatoid arthritis, Pharmaceutical industry, Cryptocurrency, Inflammation, Dostarlimab, Sanofi

Initiating a global Phase 2b trial for rosnilimab, a PD-1 agonist antibody, in rheumatoid arthritis (RA) later in Q3 2023 and a second Phase 2 trial, in an indication yet to be announced, by year-end 2023

Key Points: 
  • Initiating a global Phase 2b trial for rosnilimab, a PD-1 agonist antibody, in rheumatoid arthritis (RA) later in Q3 2023 and a second Phase 2 trial, in an indication yet to be announced, by year-end 2023
    SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the second quarter ended June 30, 2023 and provided a business update.
  • She had extensive experience at Bristol-Meyers Squibb where she led teams that advanced more than 20 compounds into clinical development.
  • Among her prior roles includes serving as Principia’s chief medical officer from 2018 until the Sanofi acquisition in September 2020.
  • Cash, cash equivalents and investments totaled $488.7 million as of June 30, 2023, compared to $584.2 million as of December 31, 2022, for a decrease of $95.5 million.

Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, August 3, 2023
Acceleration, Fucose, Asthma, CDG, Serum, IBD, John Avalos, COVID-19, Ares, PEAK, Birth, Research, Sale, Lung, BTLA, NEA, LAD, Patient, Mab, Mortality, ARE, Therapy, Glycosylation, Skin, Respiratory failure, Pharmaceutical industry, Commercial property, Vaccine, Cryptocurrency, IND

Avalo is considering out-licensing or sale of its non-core and potentially its core assets to increase focus and reduce future expenses.

Key Points: 
  • Avalo is considering out-licensing or sale of its non-core and potentially its core assets to increase focus and reduce future expenses.
  • In July of 2023, Avalo entered into a non-binding letter of intent for the potential sale of AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose).
  • Second Quarter 2023 Financial Update:
    Avalo had $6.3 million in cash and cash equivalents as of June 30, 2023, representing a $6.9 million decrease compared to December 31, 2022.
  • The net loss and net loss per share for the three months ended June 30, 2023 was largely driven by operating expenses.